CAJ | 학술논문

内分泌治疗在激素受体阳性乳腺癌治疗中的地位已受到广泛认可。芳香化酶抑制剂（ Aro-matase inhibitors，AIs）在疗效、耐受性等方面均优于他莫昔芬（Tamoxifen，TAM）。但AIs只可应用于处于绝经状态的乳腺癌患者，因此，对于三苯氧胺耐药或存在禁忌症以及存在高危因素的绝经前患者，卵巢去势无疑为她们打开了一道通往更多、更优选择的大门。手术及放疗去势因其在可逆性、可控性及副作用方面的劣势，而逐渐被药物去势所取代。本文就乳腺癌的药物卵巢去势治疗在内分泌治疗、与化疗比较等方面的新进展做一综述。
내분비치료재격소수체양성유선암치료중적지위이수도엄범인가。방향화매억제제（ Aro-matase inhibitors，AIs）재료효、내수성등방면균우우타막석분（Tamoxifen，TAM）。단AIs지가응용우처우절경상태적유선암환자，인차，대우삼분양알내약혹존재금기증이급존재고위인소적절경전환자，란소거세무의위저문타개료일도통왕경다、경우선택적대문。수술급방료거세인기재가역성、가공성급부작용방면적열세，이축점피약물거세소취대。본문취유선암적약물란소거세치료재내분비치료、여화료비교등방면적신진전주일종술。
The endocrine therapy of hormone receptor -positive breast cancer has been widely recog-nized.Aromatase inhibitors are better than tamoxifen in efficacy ,tolerability and other aspects .However,AIs is on-ly applied in the menopausal status of breast cancer patients .Therefore,for premenopausal patients with tamoxifen resistance ,the presence of contraindications or the existence of risk factors ,ovarian castration undoubtedly open a gateway to the more and better option for them .Because of the disadvantages of the reversibility, controllability and side effects ,castration surgery and radiotherapy have been gradually replaced by medical castration .In this paper , the new progress are reviewed .Our article aims to make a review on the lastest research on the new progress of breast cancer medical ovariectomized on endocrine therapy ,the comparison with chemotherapy and other aspects .